Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
HIMS Selloff Creates De-Risked Entry
10:24am, Wednesday, 11'th Feb 2026
HIMS Selloff Creates De-Risked Entry
First Look: Jobs Data Looms; WBD-NFLX Fight, Moderna Setback
07:40am, Wednesday, 11'th Feb 2026
Stock News FDA refuses to file Moderna's flu shot: Moderna (MRNA) said the FDA issued a refusal-to-file letter for its mRNA flu vaccine application, citing tria
Breakfast News: First SaaS, Now Finance Hit By AI
07:30am, Wednesday, 11'th Feb 2026
AI makes move into tax planning, Shopify and Unity report this morning, and more
GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching
07:15am, Wednesday, 11'th Feb 2026
One of the biggest trends in the fight against obesity has been the explosion in popularity of GLP-1 medications. Created to treat diabetes, patients who were prescribed the popular GLP-1 drugs Ozempi
Why Cheaper GLP-1 Drugs Are Facing Legal Battles
01:01pm, Tuesday, 10'th Feb 2026
The push to make weight loss drugs more affordable is running into legal limits. Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and risi
Novo Says It's Suing Hims to Halt Obesity Drug Copycats
12:32pm, Tuesday, 10'th Feb 2026
Bloomberg News Health Reporter Madison Muller reports on the latest on Novo's lawsuit. - Novo Nordisk said it's suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even a
Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade)
09:53am, Tuesday, 10'th Feb 2026
Downgrading Hims & Hers Health, Inc. to Hold as the GLP-1 downside catalysts feel very real now. The FDA signaled new limits on non-approved compounded GLP-1 APIs being mass-marketed, and it explicitl
First Look: Novo sues Hims, BP halts buybacks, Meta faces trial
07:39am, Tuesday, 10'th Feb 2026
Stock News Novo sues Hims over compounded weight-loss drugs: Novo Nordisk (NVO) filed suit to stop Hims and Hers Health (HIMS) from selling compounded semaglutide
Novo Nordisk opens new front with patent suit over Hims' Wegovy copies
06:04am, Tuesday, 10'th Feb 2026
Novo Nordisk's U.S. patent lawsuit against Hims & Hers , filed on Monday, marks a new front in the Danish pharmaceutical drugmaker's campaign against companies selling compounded versions of its block
Why Hims Stock Slid 40% In A Month?
05:35am, Tuesday, 10'th Feb 2026
There are two words that can cause a stock to plummet quicker than one can utter semaglutide: FDA warning. This is precisely what transpired with Hims & Hers Health Inc's shares, as Hims & Hers stock
Hims & Hers Health (NYSE:HIMS) Shares Gap Down on Analyst Downgrade
01:56am, Tuesday, 10'th Feb 2026
Hims and Hers Health, Inc. (NYSE: HIMS - Get Free Report) shares gapped down prior to trading on Monday after TD Cowen lowered their price target on the stock from $30.00 to $20.00. The stock had prev
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
06:45pm, Monday, 09'th Feb 2026
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.33, denoting a -16.05% move from the preceding trading day.
Hims & Hers Health: Don't Fall For The Hysteria
06:04pm, Monday, 09'th Feb 2026
Hims & Hers Health trades at yearly lows amid market hysteria over compounded oral Wegovy and regulatory scrutiny. The online health platform is not a GLP-1-centric company; weight-loss sales are fore
Market Today: Novo sues Hims; Highlander EV; Alphabet bond
05:36pm, Monday, 09'th Feb 2026
Guru Stock PicksChuck Royce has made the following transactions:Reduce in NATL by 11.01%Sold out in DENNAdd in SXC by 106.69%New position in AZZKen Fisher has m
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit
05:30pm, Monday, 09'th Feb 2026
Expand NYSE: HIMS Hims & Hers Health Today's Change (-16.07%) $-3.70 Current Price $19.32 Key Data Points Market Cap $5.2B Day's Range $16.36 - $19.52 52wk Range $16.36 - $72.98 Volume 4.1M Avg Vol 18
